Venturi Wealth Management LLC Acquires 2,751 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Venturi Wealth Management LLC grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 170.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,367 shares of the medical research company’s stock after acquiring an additional 2,751 shares during the period. Venturi Wealth Management LLC’s holdings in Charles River Laboratories International were worth $806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the period. State Street Corp boosted its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after buying an additional 47,221 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after buying an additional 32,311 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 1.7 %

Shares of NYSE CRL opened at $154.63 on Wednesday. The firm’s 50-day moving average price is $174.59 and its 200-day moving average price is $189.16. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of 19.35, a P/E/G ratio of 6.47 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CRL shares. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday. UBS Group reaffirmed a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).